Impact of diclofenac risk minimization measures addressing cardiovascular risk on analgesic use in musculoskeletal disorders
The observed decrease of diclofenac initiation was unrelated to patients' cardiovascular risk. Continued prescribing of systemic diclofenac to patients with contraindications suggests limited impact of RMMs. Increased time from diagnosis to analgesic treatment suggests broader changes in analgesic prescribing practices.
Authors
- Rolf H. H. Groenwold (ORCID: https://orcid.org/0000-0001-9238-6999)
- Daniala L. Weir (ORCID: https://orcid.org/0000-0001-7044-2443)
- Yared Santa‐Ana‐Téllez (ORCID: https://orcid.org/0000-0003-3086-446X)
- Satu J. Siiskonen (ORCID: https://orcid.org/0000-0003-3095-9530)
- Helga Gardarsdóttir (ORCID: https://orcid.org/0000-0001-5623-9684)
- Tomas Lasys (ORCID: https://orcid.org/0000-0002-8892-9820)
Institutions
- University of Iceland (IS)
- Utrecht University (NL)
- Leiden University Medical Center (NL)
- University Medical Center Utrecht (NL)
- Pharmo Institute (NL)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1002/bcp.70142
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00